Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (8)

2024

  1. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology, Vol. 42, Núm. 22, pp. 2702-2712

  2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

  2. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

    Leukemia